stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Current ratio
argenex SE's current ratio at the end of the quarter to 30 June 2026 was 5.1×, down 0.1× from fiscal 2025 (5.2×). Over the past ten years it has ranged from 2.4× (fiscal 2016) to 14.3× (fiscal 2018); the current reading is higher than 20% of that period. That is in line with the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.2× | (28.31%) |
| FY2024 | 7.3× | (25.23%) |
| FY2023 | 9.7× | 6.22% |
| FY2022 | 9.2× | 8.72% |
| FY2021 | 8.4× | 34.81% |
| FY2020 | 6.3× | (27.06%) |
| FY2019 | 8.6× | (39.93%) |
| FY2018 | 14.3× | 1.11% |
| FY2017 | 14.1× | 488.69% |
| FY2016 | 2.4× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 5.1× | (1.99%) |
| Dec 2025 | 5.2× | (6.59%) |
| Jun 2025 | 5.6× | (23.24%) |
| Dec 2024 | 7.3× | (14.59%) |
| 16 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 16.7× |
| RVMD Revolution Medicines, Inc. compare | 8.4× |
| ARGX argenex SE | 5.1× |
| INCY Incyte Corporation compare | 3.8× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 3.6× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 3.4× |
| GMAB Genmab A/S Sponsored ADR compare | 2.5× |
| MRNA Moderna, Inc. compare | 2.3× |
| RPRX Royalty Pharma PLC compare | 1.3× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement